Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers

Thus, we believe that intralesional application of EGF should be an option for ischemic wounds only after vascular evaluation (and intervention when possible), HBOT, NPWT, and standard care have proven insufficient.

📌 3 Maddede Bu Makale

🎯

Amaç & Hipotez:Objective: The intralesional injection of recombinant human epidermal growth factor (EGF-IL), a new therapy, has been claimed to prevent major amputations in advanced diabetic foot lesions.

📊

Temel Bulgular & Veri:In this study, the efficacy of EGF-IL on advanced diabetic foot ulcers (DFU) was reviewed.Methods: Intralesional 75 ?g EGF application (Heberprot-P® 75, Heber Biotec, Havana, Cuba) to 12 diabetic foot lesions in 11 patients (8 males, 3 females; mean age: 62.2±10.6 years) was evaluated.

💡

Sonuç & Katkı:Thus, we believe that intralesional application of EGF should be an option for ischemic wounds only after vascular evaluation (and intervention when possible), HBOT, NPWT, and standard care have proven insufficient.

🔬Tür:Literatür & Derleme Çalışması

📍Kapsam:Genişletilmiş Akademik Örneklem

⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: The intralesional injection of recombinant human epidermal growth factor (EGF-IL), a new therapy, has been claimed to prevent major amputations in advanced diabetic foot lesions. In this study, the efficacy of EGF-IL on advanced diabetic foot ulcers (DFU) was reviewed.Methods: Intralesional 75 ?g EGF application (Heberprot-P® 75, Heber Biotec, Havana, Cuba) to 12 diabetic foot lesions in 11 patients (8 males, 3 females; mean age: 62.2±10.6 years) was evaluated. Most of the patients had undergone revascularization and received hyperbaric oxygen therapy (HBOT) and negative pressure wound therapy (NPWT), along with standard care, but failed to heal. After amputation was offered as the final option, EGF-IL was applied to evaluate its effects.Results: Two patients underwent amputation, while 10 lesions of the remaining 9 patients healed completely.Conclusion: Our results prove that intralesional application of EGF can prevent amputations in advanced diabetic foot cases with an ischemic component. However, evidence in the literature supporting its use remains lacking, and its high cost presents an additional problem. Thus, we believe that intralesional application of EGF should be an option for ischemic wounds only after vascular evaluation (and intervention when possible), HBOT, NPWT, and standard care have proven insufficient.

🔖

Bu Makaleye Atıf Yap

AKTAŞ, Ş., BAKTIROĞLU, S., DEMİR, L., KILIÇOĞLU, Ö. İ., TOPALAN, M., GÜVEN, E., MİRASOĞLU, B., YANAR, F. (2016). Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers. Acta Orthopaedica et Traumatologica Turcica, Cilt: 50 - Sayı: 3, 277–283. https://ajindex.com/articles/353540

Kaynakça (10)

Wild S, Roglic G, Green A, Sicree R, King H. Global prev- alence of diabetes: estimates for the year 2000 and projec- tions for 2030. Diabetes Care 2004;27:1047-53.
Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinc- cag N, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013;28:169-80.
Satman I, Yilmaz T, Sengül A, Salman S, Salman F, Uygur S, et al. Population-based study of diabetes and risk charac- teristics in Turkey: results of the turkish diabetes epidemi- ology study (TURDEP). Diabetes Care 2002;25:1551-6.
Singh N, Armstrong DG, Lipsky BA. Preventing foot ul- cers in patients with diabetes. JAMA. 2005;293:217-28.
Frykberg RG, Armstrong DG, Giurini J, Edwards A, Kra- vette M, Kravitz S, et al. Diabetic foot disorders: a clinical practice guideline. American College of Foot and Ankle Surgeons. J Foot Ankle Surg 2000;39(5 Suppl):S1-60. Gesell LB. Hyperbaric oxygen: definition. In: Ge- sell LB (Chair & Editor) Hyperbaric Oxygen Therapy Indications.12th ed. The Hyperbaric Oxygen Therapy Committee Report. Durham, NC: UHMS. p. 4-6.
Abidia A, Laden G, Kuhan G, Johnson BF, Wilkinson AR, Renwick PM, et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double- blind randomised-controlled trial. Eur J Vasc Endovasc Surg 2003;25:513-8.
Löndahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chron- ic foot ulcers in patients with diabetes. Diabetes Care 2010;33:998-1003.
Faglia E, Favales F, Aldeghi A, Calia P, Quarantiello A, Ori- ani G, et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ul- cer. A randomized study. Diabetes Care 1996;19:1338-43.
Ubbink DT, Westerbos SJ, Evans D, Land L, Vermeulen H. Topical negative pressure for treating chronic wounds. Cochrane Database Syst Rev 2008;3:CD001898. Armstrong DG, Lavery LA; Diabetic Foot Study Con- sortium. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised con- trolled trial. Lancet 2005;366:1704-10.
Blume PA, Walters J, Payne W, Ayala J, Lantis J. Compari- son of negative pressure wound therapy using vacuum-as- sisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care 2008;31:631-6. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eru